New antihemorrhagic agents: a novel antifibrinolytic strategy

  • Hemorrhage is a leading cause of death and cost associated with blood transfusion.

  • There is a need for the improvement of current treatments of bleeding associated with  surgery, trauma, intracerebral hemorrhage (ICH) or other tissue damages.

  • A novel target involved in fibrinolysis has been identified.

  • Proprietary novel compounds to prevent major bleeding have been developed:

    • Small molecule entity (SME).

    • Efficacy: 30,000 times more effective than the currently available therapies.

    • Safety: No thrombus formation and no impact on coagulation.

  • Primary Indication: prophylaxis and acute treatment of bleeding in cardiac surgery.

>> Download information


Research Programs

Research programs in which you can participate with CIMA

CIMA Research Programs and Agreements [PDF]

"CIMA Lab Diagnostics"


Its objective is to optimize the range of genetic and immunophenotypic diagnoses carried out in different laboratories of the University of Navarra with the highest level of quality and innovation.

Go to companies

Contact us:

Contact:
Center for Applied Medical Research (CIMA)
Avenida Pío XII, 55
31008 Pamplona
Spain

+34 948 194700
cima@unav.es